Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

Following the Relevant Events issued on 27 October 2018, 29 March 2019 and 16 July 2019, in which Grifols shared the results of the AMBAR (Alzheimer Management by Albumin Replacement (phase IIb/III)) clinical trial, at the Barcelona, Lisbon and Los Angeles congresses on Alzheimer’s Disease in which primary and secondary endpoints were explained, Grifols reports that the latest results of the clinical trial have been presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA (USA).

The neuroimaging data presented show the treatment’s positive effects in reducing the progression of the disease in patients with mild-to-moderate Alzheimer’s Disease. These findings strengthen Grifols’ investigative approach using Plasma Protein Replacement Therapies.

Neuroimaging shows positive results particularly in patients receiving both albumin and immunoglobulin (IG). In comparison with the placebo group, these patients had less reduction of brain glucose metabolism over the 14 months of therapy. This suggests that neuronal damage was reduced in these patients.

In Barcelona, on 6 December 2019

Nuria Martin Barnés
Secretary to the Board of Directors